And overall survival for good responding patients (VGPR or better) is more than eight years. But this is not an absolute guarantee of permanent success, or the fabled cure.It is important to take a step back and understand what we know about long survival in myeloma patients:A good way to define cure right now is when patients live with a good quality of life and succumb to something other than myeloma—such as old age, vascular disease, or other common illnesses of the elderly. Here, CURE ® looks back at some of the latest news and updates in that space.

Katja Weisel (Stellv. First remission will be in the four-year range. Your email address is used Without maintenance treatment, researchers found, HIV rapidly rebounds, the result of reservoirs of infection. We do not guarantee individual replies due to extremely high volume of correspondence. Tuna Mutis explained the next steps: "The first step towards using this compound in the clinic is to do a phase one trial, which judges the safety of the drug. Zum Multiplen Myelom finden Sie neben der präsentierten Folie außerdem auch einen einzelnen Vortrag von Frau Prof. Dr. med.

Provided by internet news portal provides the latest news on scienceTech Xplore covers the latest engineering, electronics and technology advances Science X Network offers the most comprehensive sci-tech news coverage on the web Read the latest news and information about multiple myeloma and related conditions, including potential symptoms, causes and treatments of the disease. Currently the treatments are only able to halt the progression of the disease and relieve symptoms, but cannot cure the disease.The survival of many cancer types relies on a family of related survival proteins called BCL-2 family proteins, Professor David Huang at WEHI said.“In the past decade there has been considerable interest in the using anti-cancer agents called ‘BH3-mimetics’ to kill cancer cells by blocking the BCL-2 family proteins.”“Recent clinical trials have demonstrated that a BH3-mimetic that switches off the protein BCL-2 is an effective treatment for certain forms of leukaemia.”“Our latest research has focused on which BH3-mimetics would be the most effective in treating multiple myeloma, a cancer for which new treatments are urgently needed,” Professor Huang said.Dr Jianan Gong at WEHI said the team discovered that the majority of myeloma samples died when MCL-1 was switched off.“In contrast, only around one-quarter were susceptible to inhibiting BCL-2. There have been several updates in the field of multiple myeloma over the last several weeks. This site uses cookies to assist with navigation, analyse your use of our services, and provide content from third parties. This is the next step in the research: If MRD negative persists at one year, this is excellent.

by Worldwide Cancer Research Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease—a point when many patients currently run out of options. Potential drugs that inhibit MCL-1 are in pre-clinical development and may become a promising new treatment for multiple myeloma.

They suggest that FL118 has the potential to be highly efficient in relapsed or treatment resistant patients—a group that urgently needs new therapeutic options.Dr. You can be assured our editors closely monitor every feedback sent and will take appropriate actions. Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inbox Direktorin der II. The researchers found that not only is FL118 effective at killing multiple myeloma cells when they are surrounded by these support cells, but it was also able to reverse Using patient samples of newly diagnosed and relapsed or treatment resistant patients, FL118 was found to be more effective against cancer cells from advanced disease patients, than the newly diagnosed cases. Again, with so much in the news about the horrors of climate change, it is encouraging to note positive news.There are many good and positive things happening in the world.

Our collaborators, who also provided this compound, are now planning this trial. Might this be possible for some patents with myeloma? Understanding myeloma. .CANCERRESEARCH is a collaborative initiative facilitated by the Australian Cancer Research Foundation.

Helen Rippon, Chief Executive of Worldwide Cancer Research, said: "This study is close to our heart as Worldwide Cancer Research's founder, Dr. Colin Thomson, sadly passed away from multiple myeloma. Adding a first-of-its kind drug to a regimen for advanced multiple myeloma delayed the time until disease progression and reduced the rate of peripheral neuropathy, a side effect that causes numbness and tingling in the extremities. But what does “a cure” really mean? Infoline: 0800 980 3332 ; Office: 0131 557 3332; Understanding myeloma.